Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Tuberculosis Clinical Trial

Official title:

Phase I, Double-Blind, Randomized, Single-Center, Five-Period Crossover Study to Assess the Effects of Single Oral Doses of 400 mg and 1000 mg of PA-824 and 400 mg of PA-824 Plus 400 mg of Moxifloxacin on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male and Female Volunteers Aged 18 to 45 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01674218
• Other study ID #: 10-0058
• Secondary ID: N01AI80024C
• Status: Completed
• Phase: Phase 1
• First received: August 23, 2012
• Last updated: November 13, 2014
• Start date: September 2012
• Est. completion date: December 2012

Study information

• Verified date: March 2013
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Federal GovernmentUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, single-center, double-blinded, randomized, placebo-controlled, five-period cross-over clinical study of PA-824 to evaluate the effect of PA-824 and of PA-824 plus moxifloxacin on cardiac repolarization (QT/QTc interval duration) in a total of 75 healthy male and female participants, aged 18 to 45 years. Moxifloxacin will be used as an active control. Participants will be blinded to the treatments they will receive. The study consists of a screening period up to 26 days; enrollment, 1 day; five in-patient treatment periods consisting of an admission day (except in the first treatment period, when the pre-dose day is the baseline), dosing day and two post-dosing days; an out-patient period of at least three days and not more than 10 days between treatment periods; and a final visit 7 - 14 days after discharge from the last treatment period.

Description:

This is a Phase I, single-center, double-blinded, randomized, placebo-controlled, five-period cross-over clinical study of PA-824 to evaluate the effect of PA-824 and of PA-824 plus moxifloxacin on cardiac repolarization (QT/QTc interval duration) in healthy male and female participants. Moxifloxacin will be used as an active control. Participants will be blinded to the treatments they will receive. The study consists of a screening period up to 26 days; enrollment, 1 day; five in-patient treatment periods consisting of an admission day (except in the first treatment period, when the pre-dose day is the baseline), dosing day and two post-dosing days; an out-patient period of at least three days and not more than 10 days between treatment periods; and a final visit 7 - 14 days after discharge from the last treatment period. During the study, the subjects will receive each one of the following five treatments: Treatment A: PA-824 placebo and moxifloxacin placebo; Treatment B: PA-824 400 mg plus moxifloxacin placebo; Treatment C: PA-824 1000 mg plus moxifloxacin placebo; Treatment D: PA-824 placebo plus moxifloxacin 400 mg; Treatment E: PA-824 400 mg plus moxifloxacin 400 mg. The primary objective is to evaluate the effect of single-dose administration of PA-824 400 mg and 1000 mg versus placebo on the QTcI interval. A total of 75 randomized (in order to have at least 60 evaluable) healthy male and female volunteers, aged 18 to 45 years will be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Subject must be 18 to 45 years of age (inclusive).

• Subject must be a healthy male or female volunteer as determined by medical history, physical examination, 12-lead ECG and laboratory evaluations (hematology, clinical chemistries and urinalysis tests) within study-defined ranges at Screening. (See Appendix B for acceptable ranges of laboratory and vital signs assessments).

• Body Mass Index (BMI) must be between 18 and 30 kg/m^2 inclusive.

• Subject must be non-tobacco/nicotine using (3-month minimum).

• Subject must be Tuberculin Skin Test/Purified Protein Derivative (TST/PPD) negative (within the previous 1 year) at Screening. The TST/PPD may be omitted if the subject presents written evidence of having a negative test during the previous 12 months.

• Subject must be able to give voluntary written informed consent before any study related procedure is performed.

• If female, has no childbearing potential (as defined below) or agrees to avoid becoming pregnant from the day of screening through one week after the last dose by using one of the following acceptable methods of birth control in addition to the use of a barrier method (condom) by the male partner (even if vasectomized):

1. Hormonal contraceptives; or

2. intrauterine contraceptive device; or

3. diaphragm in combination with contraceptive jelly, cream, or foam; or

4. spermicide; or

5. abstinence. Non-childbearing potential is defined as being post-menopausal for at least 2 years, status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy or status after hysterectomy.

If male, agrees to avoid fathering a child from the day of screening to three months after the last dose.

• All female subjects must have a negative serum pregnancy test at Screening, Enrollment (Day-2) and at check-in for each treatment period.

• Subject agrees not to donate blood during the study and up to 14 days after the end of the last treatment period.

• Subject agrees to comply with all study requirements.

Exclusion Criteria:

• A history of clinically significant acute illness (resolved within 4 weeks of screening) or history of cardiac arrhythmias or unexplained syncope or presence of cardiac, vascular gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, or psychiatric disease or any other condition which, in the opinion of the Site Principal Investigator (PI), would jeopardize the safety of the subject or impact the validity of the study results.

• Subject has had major surgery within 4 weeks of screening.

• has an uncontrolled intercurrent illness (i.e., active infection) or fever (oral temperature >/=100 degrees Fahrenheit or >/= 37.7 degrees Celsius) at screening.

• History of lens opacity or evidence of lens opacity on screening ophthalmologic examination or any other clinically significant ophthalmic dysfunction or disease.

• Subject has been on an abnormal diet during the 4 weeks preceding screening. Abnormal diet is defined as a diet in which the subject has a significant change in eating habits (e.g., liquid diet only) and an unbalanced diet (e.g., protein only, high fat, low carbohydrate, etc.).

• Subject has engaged in strenuous physical activity or consumed alcohol, grapefruit, and caffeine- or methylxanthine-containing beverages from 48 hours before reporting to the clinic for enrollment until discharge from the clinical site in the last treatment period.

• Previous participation in any other study of PA-824.

• History of seizures (other than febrile seizures during childhood) or known or suspected Central Nervous System (CNS) disorders that may predispose to seizures.

• History of photosensitivity or phototoxicity reactions after use of quinolones or other drugs.

• History of allergy or severe side-effects with nitroimidazoles (e.g., Flagyl and related substances and azole antifungals or aromatase inhibitors).

• History of allergy to moxifloxacin or any fluoroquinolone antibiotic.

• History of tendinopathy associated with quinolones or other drugs, including glucocorticoids, or a condition that predisposes to tendon rupture.

• Subject has received an investigational drug in a clinical trial within 30 days prior to screening.

• Subject has used any over the counter (OTC) medication, including vitamins and herbal supplements, antacids, cough and cold medications, within 7 days prior to Day 1 of treatment with study drugs or during the study, unless in the opinion of the PI, the substance would not likely impact on the conduct of this study.

• Subject has used any prescription medication, except hormonal contraceptives, within 30 days prior to Day 1 of treatment with study drugs or during the study, unless in the opinion of the PI, the substance would not likely impact the conduct of this study.

• Subject has any current medical condition requiring treatment with medication, either prescription or OTC.

• Subject has been treated with any known CYP450 enzyme altering drugs, such as azoles, antifungals, barbiturates, phenothiazines, cimetidine, carbamazepine, etc., except hormonal contraceptives, within 30 days prior to Day 1 of treatment with study drugs.

• Subject has been treated with any drugs known to prolong the electrocardiographic QT interval within 30 days prior to Day 1 of treatment with study drugs or has history of excessive chronic caffeine (> 6-8 oz cups of brewed coffee daily), or theophylline (> 600 mg/day), or ephedrine (>300 mg/day) use..

• Subject has a positive blood screen for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody.

• Subject has a positive history for alcohol abuse or dependence and/or a positive urine screen test for alcohol and drugs of abuse [amphetamines, barbiturates, benzodiazepines, cocaine metabolites, marijuana, opiates, phencyclidine (PCP)] at screening or at any check-in prior to receiving study drugs.

• Subject has a baseline QTcF interval >440 msec (males) or >450 msec (females) or a history of prolonged QTc interval or a family history of Long QT Syndrome or premature cardiac death or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease or CHF or terminal cancer).

• Subject has any clinically significant ECG abnormality in the opinion of the site principal investigator (PI) at Screening, Enrollment (Day-2), Baseline (Day-1), and at any check-in day prior to receiving study drugs.

• Subject with ECGs deemed by the PI to have T -wave morphology unfavorable for consistently accurate QT measurement and presence of artifacts that cannot be readily eliminated.

• Subject has hypokalemia, hypomagnesemia, or hypocalcemia, or a history of eating disorder.

• Subject has serum creatinine, blood urea nitrogen (BUN) or transaminase measurements above the upper limit of the normal range at screening.

• Subject has lived with a person having active Tuberculosis (TB) or has traveled to an area of endemic TB within the past 12 months prior to Screening.

• Women who are pregnant or breastfeeding.

• Subject has donated blood within the past 30 days prior to Day 1 of treatment with study drugs.

• Subject is an employee of or family member of an employee of Quintiles, or DynPort Vaccine Company LLC (DVC) or personnel participating in the conduct of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Drug:
• Moxifloxacin
Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
• PA-824
PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Other:
• Placebo
Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Locations

Country	Name	City	State
United States	Quintiles Phase I Services - Overland Park	Overland Park	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of PA-824 on cardiac ventricular repolarization (CVR) as measured by QT interval corrected for heart rate using individual-specific formula (QTcI) during the first 24 hours following dosing of PA-824 in healthy volunteers as compared to placebo.		24 hours after dosing of PA-824	No
Secondary	Effect of PA-824 on CVR measured by QT interval corrected for heart rate by group-specific formula (QTcN), Fridericia (QTcF) and Bazett (QTcB) formulae during the first 24 hours following dosing in healthy volunteers compared to placebo.		24 hours after dosing of PA-824	No
Secondary	Effect of PA-824 plus moxifloxacin on CVR as measured by QT and QT corrected for heart rate (QTcI, QTcN, QTcF, and QTcB) during the first 24 hours following dosing of PA-824 in healthy volunteers as compared to placebo.		24 hours after dosing of PA-824	No
Secondary	The effect of Moxifloxacin on CVR as measured by QTcI, QTcN, QTcF, and QTcB, HR and non-QTc ECG intervals (HR, and PR, QRS, and RR intervals) during the first 24 hours following dosing of PA-824 in healthy volunteers as compared to placebo.		24 hours after dosing of PA-824	No
Secondary	Safety and tolerability evaluated by ophthalmology exam.		Screening , Day -2 and Day 45	Yes
Secondary	Analysis of the QTcI, QTcN, QTcF, QTcB, PR, QRS, and RR intervals and heart rate matched to PK sampling times to allow determination of any PK / pharmacodynamic effect of PA-824 alone and in combination with moxifloxacin.		Day 1 of each treatment period at 0 h (pre-dose) and 0.25, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72(±4) and 96(±4) hrs (post-dose).	No
Secondary	Safety and tolerability evaluated by standard 12-lead ECGs obtained pre-dose and 2, 4, 7 and 10 hrs post-dose on treatment days.		ECGs: pre-dose, 2, 4, 7 & 10 hrs post dose.	Yes
Secondary	Safety and tolerability evaluated by continuous AE monitoring throughout the study; physical exams, and laboratory evaluations		Day 0 to Day 45	Yes
Secondary	Serum pharmacokinetics (PK) of 400 mg and 1000 mg of PA-824 and of 400 mg of PA-824 plus 400 mg of moxifloxacin for up to 5 days following dosing.		Day 1 of each treatment period at 0 h (pre-dose) and 0.25, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72(±4) and 96(±4) hrs (post-dose).	No